Payment overview · 2025
General Payments
$578.60
29 reported records · 6 companies
Healthcare provider profile · identity verified
Young H. Lee, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FEDERAL WAY, WA · NPI 1922101500
Verified facts
What the public records show
CMS Open Payments records show Young H. Lee, MD received $578.60 in general payments during 2025 across 29 reported records.
Phathom Pharmaceuticals, Inc. accounted for 47.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Gemtesa, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 535 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $274.70 | 47.5% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $209.78 | 36.3% | 16 | 2025 |
| Fidia Pharma USA Inc. | Unresolved — no canonical attribution shown | $27.84 | 4.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $24.42 | 4.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $23.08 | 4.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.78 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $578.60 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $274.70 | 9 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $209.78 | 16 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $177.64 | 15 | 2025 |
Source payment records
|
|||||
| HYALGAN Normalized: hyalgan |
Device | Fidia Pharma USA Inc. | $27.84 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 535 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 165 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 94 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
535 | 118 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
94 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
165 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
207 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2088 | 554 |
| Losartan Potassium | Losartan Potassium | 1322 | 342 |
| Amlodipine Besylate | Amlodipine Besylate | 1292 | 316 |
| Omeprazole | Omeprazole | 953 | 264 |
| Metoprolol Succinate | Metoprolol Succinate | 742 | 178 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 666 | 195 |
| Tamsulosin Hcl | Tamsulosin Hcl | 635 | 172 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 606 | 161 |
| Levothyroxine Sodium | Levothyroxine Sodium | 593 | 153 |
| Creon | Lipase/Protease/Amylase | 535 | 118 |
| Metformin Hcl | Metformin Hcl | 533 | 157 |
| Lidocaine | Lidocaine | 437 | 84 |
| Gabapentin | Gabapentin | 416 | 123 |
| Simvastatin | Simvastatin | 407 | 92 |
| Diclofenac Sodium | Diclofenac Sodium | 388 | 148 |
| Montelukast Sodium | Montelukast Sodium | 353 | 88 |
| Pantoprazole Sodium | Pantoprazole Sodium | 342 | 89 |
| Lisinopril | Lisinopril | 324 | 94 |
| Metformin Hcl Er | Metformin Hcl | 323 | 88 |
| Finasteride | Finasteride | 322 | 82 |
| Januvia | Sitagliptin Phosphate | 317 | 66 |
| Memantine Hcl Er | Memantine Hcl | 314 | 77 |
| Calcitriol | Calcitriol | 303 | 36 |
| Jardiance | Empagliflozin | 299 | 70 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 299 | 77 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 290 | 190 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 278 | 50 |
| Donepezil Hcl | Donepezil Hcl | 259 | 53 |
| Furosemide | Furosemide | 254 | 73 |
| Vascepa | Icosapent Ethyl | 254 | 54 |
| Famotidine | Famotidine | 253 | 65 |
| Glipizide Er | Glipizide | 226 | 55 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 216 | 39 |
| Tramadol Hcl | Tramadol Hcl | 214 | 87 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 207 | 68 |
| Ozempic | Semaglutide | 207 | 37 |
| Trazodone Hcl | Trazodone Hcl | 207 | 61 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 201 | 58 |
| Sertraline Hcl | Sertraline Hcl | 198 | 54 |
| Myrbetriq | Mirabegron | 187 | 38 |
| Carvedilol | Carvedilol | 169 | 43 |
| Raloxifene Hcl | Raloxifene Hcl | 168 | 44 |
| Glimepiride | Glimepiride | 167 | 36 |
| Eliquis | Apixaban | 165 | 31 |
| Potassium Chloride | Potassium Chloride | 162 | 46 |
| Celecoxib | Celecoxib | 159 | 79 |
| Allopurinol | Allopurinol | 158 | 44 |
| Azithromycin | Azithromycin | 158 | 133 |
| Fluticasone Propionate | Fluticasone Propionate | 158 | 58 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 158 | 37 |
| Valsartan | Valsartan | 154 | 35 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 146 | 120 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 133 | 39 |
| Farxiga | Dapagliflozin Propanediol | 130 | 22 |
| Prolia | Denosumab | 130 | 85 |
| Xarelto | Rivaroxaban | 129 | 33 |
| Ketoconazole | Ketoconazole | 125 | 44 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 124 | 51 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 122 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 121 | 29 |
| Memantine Hcl | Memantine Hcl | 120 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 118 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 115 | 21 |
| Prednisone | Prednisone | 115 | 65 |
| Alendronate Sodium | Alendronate Sodium | 109 | 41 |
| Amoxicillin | Amoxicillin | 109 | 67 |
| Atenolol | Atenolol | 108 | 29 |
| Restasis | Cyclosporine | 106 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 105 | 32 |
| Tradjenta | Linagliptin | 103 | 21 |
| Alprazolam | Alprazolam | 102 | 36 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 102 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 101 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 97 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 96 | 24 |
| Linzess | Linaclotide | 94 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 94 | 19 |
| Lorazepam | Lorazepam | 88 | 32 |
| Oxycodone Hcl | Oxycodone Hcl | 87 | 20 |
| Meclizine Hcl | Meclizine Hcl | 86 | 50 |
| Temazepam | Temazepam | 86 | 31 |
| Cephalexin | Cephalexin | 84 | 69 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 17 |
| Ezetimibe | Ezetimibe | 74 | 26 |
| Ibuprofen | Ibuprofen | 74 | 50 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 73 | 18 |
| Meloxicam | Meloxicam | 72 | 28 |
| Baclofen | Baclofen | 70 | 51 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 69 | 24 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 68 | 12 |
| Glipizide | Glipizide | 67 | 26 |
| Risperidone | Risperidone | 65 | 15 |
| Methotrexate | Methotrexate Sodium | 64 | 12 |
| Azelastine Hcl | Azelastine Hcl | 61 | 13 |
| Spironolactone | Spironolactone | 61 | 15 |
| Clobetasol Propionate | Clobetasol Propionate | 60 | 42 |
| Clonazepam | Clonazepam | 59 | 20 |
| Ammonium Lactate | Ammonium Lactate | 58 | 16 |
| Lovastatin | Lovastatin | 58 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 58 | 19 |
| Hydrocortisone | Hydrocortisone | 56 | 22 |
| Trulicity | Dulaglutide | 56 | suppressed |
| Mirtazapine | Mirtazapine | 54 | 13 |
| Pregabalin | Pregabalin | 53 | 17 |
| Ibandronate Sodium | Ibandronate Sodium | 49 | 15 |
| Zenpep | Lipase/Protease/Amylase | 48 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 47 | suppressed |
| Acyclovir | Acyclovir | 46 | 24 |
| Entecavir | Entecavir | 45 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 44 | suppressed |
| Cefdinir | Cefdinir | 43 | 40 |
| Ciclopirox | Ciclopirox | 43 | 25 |
| Megestrol Acetate | Megestrol Acetate | 43 | 30 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 43 | 11 |
| Entresto | Sacubitril/Valsartan | 42 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 15 |
| Lansoprazole | Lansoprazole | 41 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 41 | 13 |
| Benazepril Hcl | Benazepril Hcl | 40 | 13 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 40 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 39 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 25 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 38 | 25 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 38 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 13 |
| Unifine Pentips | Pen Needle, Diabetic | 38 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Nifedipine Er | Nifedipine | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | 16 |
| Nitroglycerin | Nitroglycerin | 36 | 29 |
| Rybelsus | Semaglutide | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Dutasteride | Dutasteride | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 17 |
| Sucralfate | Sucralfate | 30 | 14 |
| Loperamide | Loperamide Hcl | 29 | 18 |
| Mupirocin | Mupirocin | 29 | 26 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 28 | suppressed |
| Famciclovir | Famciclovir | 28 | 25 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Livalo | Pitavastatin Calcium | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 17 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 27 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 23 |
| Torsemide | Torsemide | 27 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Minoxidil | Minoxidil | 24 | suppressed |
| Oxycontin | Oxycodone Hcl | 24 | suppressed |
| Procto-Med Hc | Hydrocortisone | 24 | 15 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 23 | 17 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 23 | 11 |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 21 | suppressed |
| Gemtesa | Vibegron | 21 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 21 | 11 |
| Acarbose | Acarbose | 20 | suppressed |
| Belsomra | Suvorexant | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Colchicine | Colchicine | 19 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 18 | 11 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 18 | 18 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | 13 |
| Ondansetron Odt | Ondansetron | 17 | 12 |
| Ssd | Silver Sulfadiazine | 17 | 13 |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Nexium | Esomeprazole Magnesium | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Ofloxacin | Ofloxacin | 15 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Naproxen | Naproxen | 14 | 11 |
| Neupro | Rotigotine | 14 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 14 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $578.60 · 29 records | Phathom Pharmaceuticals, Inc. | CREON, ELIQUIS, GEMTESA, HYALGAN, LINZESS, VIBERZI, VOQUEZNA, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error